100% satisfaction guarantee Immediately available after payment Both online and in PDF No strings attached
logo-home
Samenvatting Deel Diabetes - Metabolism & Hormones 2 $8.81
Add to cart

Summary

Samenvatting Deel Diabetes - Metabolism & Hormones 2

 1 view  0 purchase
  • Course
  • Institution

Samenvatting Deel Diabetes - Metabolism & Hormones 2 Lessen hierin - Definitie en diagnose - Acute complicaties - Chronische microvasculaire complicaties - Chronische macrovasculaire complicaties - Diabetische voet - Behandeling T1 insuline - Behandeling T2 oraal - Behandeling T2 ...

[Show more]

Preview 4 out of 54  pages

  • January 4, 2025
  • 54
  • 2024/2025
  • Summary
avatar-seller
METABOLISM & HORMONES 2
Diabetes




1

,Table of Contents
1 Diabetes: definitie, classificatie en diagnose................................................................................................ 6
Definitie.................................................................................................................................................................6
Epidemiologie.......................................................................................................................................................6
Risicoinschatting...................................................................................................................................................6
Diagnose...............................................................................................................................................................6
Types.....................................................................................................................................................................7
Zwangerschapsdiabetes.......................................................................................................................................7
Monogenetische vormen......................................................................................................................................7
Andere vormen.....................................................................................................................................................7
Type 1....................................................................................................................................................................8
LADA.................................................................................................................................................................8
Genetisch..........................................................................................................................................................8
Pathogenese.....................................................................................................................................................8
Symptomen.......................................................................................................................................................9
Verschillen type 1 en type 2..................................................................................................................................9
Type 2....................................................................................................................................................................9
8 features (pathogenese)..................................................................................................................................9
Samengevatte kenmerken type 2...................................................................................................................10

2 Diabetes: acute complicaties..................................................................................................................... 11
Hypoglycemie.....................................................................................................................................................11
Symptomen.....................................................................................................................................................11
Soorten coma’s...............................................................................................................................................11
Ernst................................................................................................................................................................12
Risico...............................................................................................................................................................12
Prevalentie bij antidiabetica...........................................................................................................................12
Effecten...........................................................................................................................................................12
Counterregulatoire mechanismes..................................................................................................................13
Behandeling....................................................................................................................................................13
Diabetische keto-acidotische coma....................................................................................................................14
Wanneer ketonen monitoren?.......................................................................................................................14
DKA metabole gevolgen.................................................................................................................................15
Symptomen ernstige decompensatie.............................................................................................................15
Urgentiemaatregelen......................................................................................................................................15
Complicaties...................................................................................................................................................15
Opvolging........................................................................................................................................................16
Euglycemische keto-acidose bij SGLT-2 inhibitoren............................................................................................16
Euglycemische ketoacidose - waarom ketonen?............................................................................................16
SGLT2-i in type 1 en 2.....................................................................................................................................16
Wanneer ketonen monitoren.........................................................................................................................16
SGLT2-1 in type 1............................................................................................................................................17
Hyperosmolair non-ketotisch hyperglycemisch coma (dehydratatie)................................................................17
Hyperglycemisch coma...................................................................................................................................17

2

, Symptomen.....................................................................................................................................................17
Labo................................................................................................................................................................17
Behandeling....................................................................................................................................................17
Complicaties...................................................................................................................................................17

3 Diabetes: chronische microvasculaire complicaties....................................................................................18
HbA1c..................................................................................................................................................................18
Prevalentie..........................................................................................................................................................18
Pathogenese.......................................................................................................................................................19
Risicofactoren.................................................................................................................................................19
Retinopathie.......................................................................................................................................................19
Prevalentie......................................................................................................................................................19
Pathogenese...................................................................................................................................................19
Symtomen.......................................................................................................................................................20
Onderzoek......................................................................................................................................................20
Behandeling....................................................................................................................................................20
Nefropathie.........................................................................................................................................................20
Prevalentie......................................................................................................................................................20
Stadia..............................................................................................................................................................20
Pathogenese...................................................................................................................................................21
Complicaties nefropathie...............................................................................................................................22
Behandeling....................................................................................................................................................22
Neuropathie........................................................................................................................................................23
Definitie..........................................................................................................................................................23
Prevalentie......................................................................................................................................................23
Risicofactoren.................................................................................................................................................23
Pathogenese...................................................................................................................................................24
Symptomen.....................................................................................................................................................24
Diagnose.........................................................................................................................................................24
Chronische symmetrische polyneuropathie...................................................................................................25
Acute symmetrische polyneuropathie...........................................................................................................25
Assymetrische polyneuropathie.....................................................................................................................25
Preventie.........................................................................................................................................................25
Behandeling....................................................................................................................................................25
Autonome neuropathie..................................................................................................................................26

4 Diabetes: chronische macrovasculaire complicaties...................................................................................27
Epidemiologie.................................................................................................................................................27
Hart- en vaatziekten.......................................................................................................................................27
Huidcomplicaties............................................................................................................................................28
Tandcomplicaties............................................................................................................................................28
Infecties..........................................................................................................................................................28
Diabetische voet.............................................................................................................................................28
Vroegtijdige diagnose van belang...................................................................................................................29

5 Diabetes: diabetische voet........................................................................................................................ 29
Epidemiologie.....................................................................................................................................................29
Pathofysiologie...................................................................................................................................................29
Neuropathie....................................................................................................................................................30

3

, Orthopedische abnormaliteiten.....................................................................................................................30
Angiopathie....................................................................................................................................................31
Infectie............................................................................................................................................................31
Classificatie.........................................................................................................................................................32
Behandeling........................................................................................................................................................32
Neuropathie....................................................................................................................................................32
Orthopedische problemen.............................................................................................................................32
Angiopathie....................................................................................................................................................32
Infectie............................................................................................................................................................33
Preventie.............................................................................................................................................................33

6 Diabetes: behandeling T1 insuline............................................................................................................. 34
Insuline................................................................................................................................................................34
Geschiedenis...................................................................................................................................................34
Insuline bij niet-diabetici................................................................................................................................34
Insulinetherapie..................................................................................................................................................34
Soorten...........................................................................................................................................................34
Actieprofielen.................................................................................................................................................34
Therapeutische doelen...................................................................................................................................34
Insulineabsorptie............................................................................................................................................34
Bolus insuline......................................................................................................................................................35
Nieuwe ultrasnelwerkende insulines.............................................................................................................35
Basale insuline....................................................................................................................................................35
Voordelen.......................................................................................................................................................35
Langere werking.............................................................................................................................................36
Ideale basale therapie....................................................................................................................................36
Tweede generatie...........................................................................................................................................36
Nieuwe mogelijkheden.......................................................................................................................................36
Gglucosemonitoring.......................................................................................................................................36
Insulinepomp..................................................................................................................................................37
Targets................................................................................................................................................................37

7 Diabetes: behandeling T2 orale anti-diabetica...........................................................................................38
Doelen.................................................................................................................................................................38
Mogelijkheden....................................................................................................................................................38
Metformine.........................................................................................................................................................40
Sylfonylurea........................................................................................................................................................41
Glinidines: NovoNorm.........................................................................................................................................41
Thiazolidinedionea: glitazones...........................................................................................................................42
Incretines............................................................................................................................................................42
DPP4-inhibitoren:................................................................................................................................................42
SGLT2-inhibitoren................................................................................................................................................43

8 Diabetes: behandeling T2 injecteerbare anti-diabetica...............................................................................44


4

The benefits of buying summaries with Stuvia:

Guaranteed quality through customer reviews

Guaranteed quality through customer reviews

Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.

Quick and easy check-out

Quick and easy check-out

You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.

Focus on what matters

Focus on what matters

Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!

Frequently asked questions

What do I get when I buy this document?

You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.

Satisfaction guarantee: how does it work?

Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.

Who am I buying these notes from?

Stuvia is a marketplace, so you are not buying this document from us, but from seller adrianadane. Stuvia facilitates payment to the seller.

Will I be stuck with a subscription?

No, you only buy these notes for $8.81. You're not tied to anything after your purchase.

Can Stuvia be trusted?

4.6 stars on Google & Trustpilot (+1000 reviews)

51683 documents were sold in the last 30 days

Founded in 2010, the go-to place to buy study notes for 15 years now

Start selling
$8.81
  • (0)
Add to cart
Added